b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30910440</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>06</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1534-4436</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>122</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>06</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology</Title>\n                <ISOAbbreviation>Ann. Allergy Asthma Immunol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>630-638.e3</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S1081-1206(19)30196-6</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anai.2019.03.017</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">GSP301 nasal spray is a fixed-dose combination of olopatadine hydrochloride (antihistamine) and mometasone furoate (corticosteroid).</AbstractText>\n                <AbstractText Label="OBJECTIVE">To evaluate the efficacy and safety of GSP301 in patients with seasonal allergic rhinitis (SAR).</AbstractText>\n                <AbstractText Label="METHODS">In this double-blind study, eligible patients (\xe2\x89\xa512 years of age) with SAR were randomized 1:1:1:1 to twice-daily GSP301 (665 \xce\xbcg of olopatadine and 25 \xce\xbcg of mometasone), olopatadine (665 \xce\xbcg), mometasone (25 \xce\xbcg), or placebo for 14 days. The primary end point-mean change from baseline in average morning and evening 12-hour reflective Total Nasal Symptom Score (rTNSS)-was analyzed via a mixed-effect model repeated measures (P &lt; .05 was considered to be statistically significant). Additional assessments included average morning and evening 12-hour instantaneous TNSS (iTNSS), ocular symptoms, individual symptoms, onset of action, quality of life, and adverse events (AEs).</AbstractText>\n                <AbstractText Label="RESULTS">A total of 1176 patients were randomized. GSP301 provided statistically significant and clinically meaningful rTNSS improvements vs placebo (least squares mean difference, -1.09; 95% CI, -1.49 to -0.69; P\xc2\xa0&lt;\xc2\xa0.001) and vs olopatadine (P\xc2\xa0= .03) and mometasone (P\xc2\xa0= .02). Similar significant improvements in iTNSS were also observed with GSP301 (P &lt; .05 for all). Furthermore, GSP301 significantly improved overall ocular symptoms, individual nasal and ocular symptoms, and quality of life vs placebo (P \xe2\x89\xa4 .001 for all). Onset of action for GSP301 was observed within 15 minutes and was maintained at all subsequent timepoints. Treatment-emergent AEs occurred in 15.6%, 12.6%, 9.6%, and 9.5% of patients in the GSP301, olopatadine, mometasone, and placebo groups, respectively.</AbstractText>\n                <AbstractText Label="CONCLUSION">GSP301 is efficacious and well tolerated vs placebo for treating SAR-associated nasal and ocular symptoms, with a rapid onset of action of 15 minutes in adult and adolescent patients 12 years and older.</AbstractText>\n                <AbstractText Label="CLINICAL TRIAL REGISTRATION">ClinicalTrials.gov: NCT02870205.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Gross</LastName>\n                    <ForeName>Gary N</ForeName>\n                    <Initials>GN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Pharmaceutical Research &amp; Consulting Inc, Dallas, Texas. Electronic address: gary.gross@daac-prc.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Berman</LastName>\n                    <ForeName>Gary</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical Research Institute Inc, Minneapolis, Minnesota.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Amar</LastName>\n                    <ForeName>Niran J</ForeName>\n                    <Initials>NJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Allergy Asthma Research Institute, Waco, Texas.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Caracta</LastName>\n                    <ForeName>Cynthia F</ForeName>\n                    <Initials>CF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Glenmark Pharmaceuticals Inc, Paramus, New Jersey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tantry</LastName>\n                    <ForeName>Sudeesh K</ForeName>\n                    <Initials>SK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Glenmark Pharmaceuticals Inc, Paramus, New Jersey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ClinicalTrials.gov</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>NCT02870205</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <PublicationTypeList>\n                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>\n            <NlmUniqueID>9503580</NlmUniqueID>\n            <ISSNLinking>1081-1206</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D059085">Nasal Sprays</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>04201GDN4R</RegistryNumber>\n                <NameOfSubstance UI="D000068656">Mometasone Furoate</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>2XG66W44KF</RegistryNumber>\n                <NameOfSubstance UI="D000069605">Olopatadine Hydrochloride</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000068656" MajorTopicYN="N">Mometasone Furoate</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D059085" MajorTopicYN="N">Nasal Sprays</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069605" MajorTopicYN="N">Olopatadine Hydrochloride</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006255" MajorTopicYN="N">Rhinitis, Allergic, Seasonal</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>28</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>15</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30910440</ArticleId>\n            <ArticleId IdType="pii">S1081-1206(19)30196-6</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.anai.2019.03.017</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'